Adaptin Bio
Adaptin Bio Inc. (OTCQB: APTN) is a clinical-stage biopharmaceutical company developing novel therapeutics targeting metabolic diseases including obesity, type 2 diabetes, and related conditions. According to adaptinbio.com, the company's pipeline focuses on peripheral mechanisms designed to reduce CNS-related side effects associated with older metabolic therapies.
Based in Charlotte, North Carolina, Adaptin Bio is led by a pharmaceutical development and regulatory team advancing its lead candidates through preclinical and early clinical stages. The company began trading on the OTCQB in April 2026 following completion of a merger transaction.
Adaptin Bio is building its clinical data package to support future regulatory filings. Full program information is available at adaptinbio.com.